Summary:
If you or a family member have Sickle Cell Disease (SCD) you may want to consider the HOPE clinical research study.
What is the purpose of the HOPE study?
The HOPE study will evaluate whether an investigational medication will be safe and effective in reducing anemia, pain crises, fatigue, and other day-to-day symptoms in adolescents and adults with SCD. An investigational medication means that it has not been approved for use by the Food and Drug Administration (FDA) or other regulatory agencies.
What is the investigational medication?
GBT440 is a potential therapy for patients with SCD that is designed to attack the cause of the disease. It is designed to work by keeping hemoglobin molecules in the red blood cells from sticking to each other. This may help red blood cells keep their normal shape and may stop sickling.
Who can participate in the HOPE study?
You may be able to participate in this study if you:
- Are between 12 and 65 years of age
- Have been diagnosed with SCD
- Have had at least one pain crisis in the past year
How long is the study?
If you are eligible for the study, your participation will last at least 2.5 months and up to 1.5 years